SPL — Starpharma Holdings Share Price
0.000.00%
Last trade - 00:00- AU$169.38m
- AU$156.38m
- AU$5.85m
- 38
- 19
- 96
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.92 | ||
| Price to Tang. Book | 8.92 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 28.95 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -49.47% | ||
| Return on Equity | -42.41% | ||
| Operating Margin | -170.77% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 2.15 | 4.9 | 4.21 | 9.76 | 5.85 | 15.8 | 24 | -2.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.
Directors
- Robert Thomas NEC (75)
- Jacinth Fairley CEO (57)
- Nigel Baade CFO
- David Owen VPR
- Jeremy Paull VPR
- A Tony Eglezos VBD
- Lynda Cheng NID
- David Mcintyre NID (49)
- Zita Peach NID
- Last Annual
- June 30th, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- May 13th, 1997
- Public Since
- September 28th, 2000
- No. of Shareholders
- 3,611
- No. of Employees
- 50
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 418,224,781
- Address
- 4-6 Southampton Crescent, Abbotsford, MELBOURNE, 3067
- Web
- https://www.starpharma.com/
- Phone
- +61 385322700
- Auditors
- PricewaterhouseCoopers
Upcoming Events for SPL
Similar to SPL
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Avecho Biotechnology
Australian Stock Exchange - SEATS
FAQ
What is the Starpharma Holdings share price?
As of Today at 22:26 UTC, shares in Starpharma Holdings are trading at AU$0.41. This share price information is delayed by 15 minutes.
How has the Starpharma Holdings share price performed this year?
Shares in Starpharma Holdings last closed at AU$0.41 and the price had moved by +285.71% over the past 365 days. In terms of relative price strength the Starpharma Holdings share price has outperformed the ASX All Ordinaries Index by +276.26% over the past year.
What are the analyst and broker recommendations for Starpharma Holdings?
The overall consensus recommendation for Starpharma Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Starpharma Holdings dividend yield?
Starpharma Holdings does not currently pay a dividend.
Does Starpharma Holdings pay a dividend?
Starpharma Holdings does not currently pay a dividend.
When does Starpharma Holdings next pay dividends?
Starpharma Holdings does not currently pay a dividend.
How do I buy Starpharma Holdings shares?
To buy shares in Starpharma Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Starpharma Holdings?
As of the previous close price of AU$0.41, shares in Starpharma Holdings had a market capitalisation of AU$169.38m.
Where are Starpharma Holdings shares listed?
Here are the trading details for Starpharma Holdings:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: SPL
What kind of share is Starpharma Holdings?
Based on an overall assessment of its quality, value and momentum Starpharma Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Starpharma Holdings share price forecast for 2025?
The analyst consensus target price for shares in Starpharma Holdings is AU$0.55. That is 35.8% above the last closing price of AU$0.41.
Analysts covering Starpharma Holdings currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.60 for the next financial year.
Find out moreWhat is the trend in the Starpharma Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Starpharma Holdings. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +350.84%.
As of the last closing price of AU$0.41, shares in Starpharma Holdings were trading +155.3% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Starpharma Holdings PE Ratio?
The Starpharma Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Starpharma Holdings?
Starpharma Holdings' management team is headed by:
- Robert Thomas - NEC
- Jacinth Fairley - CEO
- Nigel Baade - CFO
- David Owen - VPR
- Jeremy Paull - VPR
- A Tony Eglezos - VBD
- Lynda Cheng - NID
- David Mcintyre - NID
- Zita Peach - NID